Upcoming Events

Stay tuned for more details!

Learn More
Comprehensive Predictive and Pharmacodynamic Biomarker Evaluations Optimized to Preserve Precious Clinical Trial Samples

Event Date: December 7, 2021

Comprehensive biomarker profiling is crucial for executing successful precision oncology programs. Common obstacles to completing biomarker profiling studies, especially in retrospective exploratory biomarker research, are the lack of sufficient sample volume and low quality of clinical trial samples. In this presentation, Discovery Life Sciences (Discovery) will describe optimized approaches to performing genomic, proteomic, and cell-based biomarker analysis from low quantity, and in some cases low quality, clinical trial samples with a single chain of sample custody to make the most efficient use of these precious samples. Discovery’s optimized protocols and processes facilitate more comprehensive biomarker analyses from each patient than was possible in the past, with the goal of enabling faster and more accurate targeting of therapies to the right populations.

Donald A. Skifter, PhD, MBA

Donald A. Skifter, PhD, MBA
SVP, Genomics
Discovery Life Sciences

Don received his PhD in pharmacology and neuroscience focusing on the molecular and genetic mechanisms of learning and memory at the University of Nebraska Medical Center in 2002. He received his MBA from the University of Nebraska Omaha in 2001. On the heels of the completion of the human genome project in 2003, following a post-doctoral fellowship in Cambridge, MA, he pursued a career in the commercialization of genomic technologies and next generation sequencing services with particular expertise in facilitating oncology genomic biomarker programs. Don’s work history includes Commercial and Technical Application Support leadership roles at several genomic technology and services companies including Invitrogen (now Thermo Fisher Scientific), Sequenom (now Agena Bioscience), Complete Genomics (IPO in 2010), the Broad Institute, and OneOme (a start-up pharmacogenomics spinout of the Mayo Clinic). He currently serves as the Senior Vice President, Genomics within the HudsonAlpha Discovery Genomics division of Discovery Life Sciences.

8th Digital Pathology & AI Congress: Europe
Event Date: December 1-2, 2021

Global Engage’s 8th Digital Pathology & AI Congress Europe  will be held face to face at the London Heathrow Marriott on December 1-2. Continuing on from the sold-out meetings of the past, the event will attract over 450 participants and 40+ exhibitors. The London event will continue to showcase some of the most exciting cutting-edge strategies and analysis techniques as well as cover important issues related to implementation and daily use in the era of Covid-19. It will also explore the continued advances in artificial intelligence and image analysis tools so that digital pathology can be utilized to its full potential. It will also have a dedicated track which focuses on the use of digital pathology in drug discovery with a focus on both clinical and non-clinical applications.

Stop by booth #39 to meet Oliver Lehner, VP Business Development EMEA at Discovery Life Sciences; Christiaan Neeleman, President Global Tissue Biomarker Services & European Operations at Discovery Life Sciences; and Dirk Zielinski, Head of Assay Development at Discovery. We’ll be ready to share our experience in Multiplex IF and IHC projects as well as our combined Targos Molecular Pathology GmbH and Discovery genomics, IHC, and biospecimens product and service portfolios.

The Digital Pathology & AI Congress’ agenda includes: Digital Pathology – Implementation – Strategy, Technology & Applications; AI for Imaging and Digital Image Analysis; Computational Pathology & AI; Pharma/Biotech Case Studies.

Register Now
DLS Booth 39

Watch On-Demand Videos

Past Events
“Cutting Edge Conversations,” Webinar with Scientist.com

“Cutting Edge Conversations,” Webinar with Scientist.com

Challenges in Sourcing Human Biosamples

Transforming drug development with accurate and scalable long-read sequencing services

Transforming drug development with accurate and scalable long-read sequencing services

The advantages of HudsonAlpha Discovery’s PacBio long-read sequencing services

Accelerate Precision Oncology with SpecimenSeq

Accelerate Precision Oncology with SpecimenSeq

NGS characterized matched FFPE and plasma biospecimens

PACBIO Global Summit Presentation Video 2020

PACBIO Global Summit Presentation Video 2020

Reliable Nucleotide, InDel, and Structural Variant Detection in Diverse Populations